Publications by Professor Farhad Kamali - ePrints

Browsing publications by Professor Farhad Kamali.

Newcastle Authors	Title	Year
Raya Vinogradov Dr Oisín Kavanagh Dr Jeremy Palmer Dr Emma Curtis Professor Farhad Kamali et al.	A randomized crossover design study comparing the pharmacokinetics and pharmacodynamics of 2 single doses of oral aspirin (75 mg v 150 mg) in pregnant women at risk of preeclampsia: implications on assessing aspirin response and patient adherence to therapy	2024
Dr Emma Kampouraki Dr Peter Avery Dr Tina Biss Dr Hilary Wynne Professor Farhad Kamali et al.	Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients	2021
Frances Sidgwick Dr Andrew Porter Dr Paul Ayuk Professor Farhad Kamali	Determination of Dabigatran Concentration in Human Plasma and Breast Milk	2021
Dr Emma Kampouraki Dr Salah Abohelaika Dr Peter Avery Dr Tina Biss Dr Hilary Wynne et al.	Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing	2021
Dr Tina Biss Professor Farhad Kamali	CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis	2020
Emma Kampouraki Dr Hilary Wynne Dr Peter Avery Professor Farhad Kamali	Validation of an algorithm to predict decline in INR following warfarin cessation in patients undergoing invasive procedures	2020
Dr Paul Ayuk Dr Emma Kampouraki Frances Sidgwick Professor Farhad Kamali	Investigation of dabigatran secretion into breast milk: Implications for oral thromboprophylaxis in post-partum women	2019
Dr Emma Kampouraki Professor Farhad Kamali	Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation	2019
Dr Paul Bogowicz Dr Eilish Gilvarry Professor Farhad Kamali Professor Eileen Kaner Professor Dorothy Newbury-Birch et al.	Alcohol and other substance use among medical and law students at a UK university: a cross-sectional questionnaire survey	2018
Dr Salah Abohelaika Dr Hilary Wynne Dr Peter Avery Dr Emma Kampouraki Professor Farhad Kamali et al.	Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery	2018
Sal Bakar Dr Peter Avery Dr Colin Brown Professor Ann Daly Professor Farhad Kamali et al.	Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case–Control Study	2018
Dr Salah Abohelaika Dr Hilary Wynne Dr Peter Avery Dr Lisa Jones Professor Farhad Kamali et al.	Individual and monitoring centre influences upon anticoagulation control of AF patients on warfarin: a longitudinal multi-centre UK-based study	2018
Dr Peter Avery Professor Farhad Kamali	Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients	2018
Dr Emma Kampouraki Dr Peter Avery Dr Hilary Wynne Dr Tina Biss Dr John Hanley et al.	Assessment of the efficacy of a novel tailored vitamin K dosing regimen in lowering the International Normalised Ratio in over-anticoagulated patients: A randomised clinical trial	2017
Dr Emma Kampouraki Dr Peter Avery Dr Tina Biss Professor Farhad Kamali	Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin therapy: Possible long-term implications for bone development and vascular health	2017
Dr Emma Kampouraki Professor Farhad Kamali	Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease	2017
Professor Ann Daly Professor Farhad Kamali	A multi-factorial analysis of response to warfarin in a UK prospective cohort	2016
Professor Farhad Kamali	Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden	2016
Sal Bakar Professor Farhad Kamali Dr Colin Brown	Effect of Statins on Functional Expression of Membrane Transporters in L6 Rat Skeletal Muscle Cells	2016
Salah Abohelaika Dr Hilary Wynne Dr Peter Avery Dr Patrick Kesteven Professor Farhad Kamali et al.	Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management	2016
Salah Abohelaika Dr Hilary Wynne Dr Peter Avery Professor Farhad Kamali	Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery	2015
Professor Farhad Kamali Professor Ann Daly	Oral anticoagulation: a critique of recent advances and controversies	2015
Professor Farhad Kamali Professor Ann Daly	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants	2015
Dr Salah Abohelaika Dr Hilary Wynne Professor Farhad Kamali	The effect of CYP2C9 polymorphism on inr decline in patients stopping warfarin before surgery	2015
Salah Abohelaika Dr Hilary Wynne Professor Farhad Kamali	The impact of genetics on the management of patients on warfarin awaiting surgery	2015
Salah Abohelaika Professor Farhad Kamali Dr Peter Avery Dr Patrick Kesteven Dr Hilary Wynne et al.	Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England	2014
Salah Abohelaika Dr Tina Biss Dr Hilary Wynne Professor Farhad Kamali	C0170: The Impact of Dietary Vitamin K on the Pharmacological Activity of FXa Inhibitor Rivaroxaban in Man	2014
Dr Tina Biss Professor Farhad Kamali	Characterizing variability in warfarin dose requirements in children using modelling and simulation	2014
Professor Farhad Kamali	Genotype-Guided Dosing of Vitamin K Antagonists [Reply]	2014
Dr Tina Biss Dr Peter Avery Emily Swinburne Professor Farhad Kamali	Maintenance warfarin dose in children is determined by S-warfarin clearance which is in turn influenced by CYP2C9 genotype	2014
Professor Ann Daly Professor Farhad Kamali	Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy	2014
Salah Abohelaika Dr Tina Biss Dr Peter Murphy Professor Farhad Kamali	The impact of dietary vitamin K on the pharmacological activity of FXa inhibitor rivaroxaban in man	2014
Dr Patrick Kesteven Professor Ann Daly Dr Peter Avery Professor Farhad Kamali	A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study	2013
Dr Patrick Kesteven Julian Leathart Professor Ann Daly Professor Farhad Kamali	A Randomized Trial of Genotype-Guided Dosing of Warfarin	2013
Professor Farhad Kamali Dr Hilary Wynne Dr Patrick Kesteven Dr John Hanley Dr Jing Shen et al.	Improving the safety and efficacy of anticoagulation therapy for thromboembolic disease through Vitamin K	2013
Dr Jeremy Palmer Professor Farhad Kamali	Quality of bevacizumab compounded for intravitreal administration	2013
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children	2013
Professor Ann Daly Professor Farhad Kamali	Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs	2012
Professor Farhad Kamali	Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users	2012
Professor Farhad Kamali	Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data	2012
Dr Ellen Hatch Dr Iain Matthews Professor Ann Daly Professor Farhad Kamali	The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors	2012
Dr Tina Biss Dr Peter Avery Julian Leathart Professor Farhad Kamali	VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children	2012
Dr Tina Biss Professor Farhad Kamali	Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?	2012
Dr Tina Biss Dr Peter Avery Julian Leathart Professor Farhad Kamali	Warfarin dose prediction in children using pharmacogenetics information	2012
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	Warfarin dose prediction in children using pharmacogenetics information	2012
Dr Tina Biss Dr Peter Avery Julian Leathart Dr John Hanley Professor Ann Daly et al.	VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children	2011
Professor Farhad Kamali	Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data	2011
Dr Peter Avery Professor Farhad Kamali	A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy	2011
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children	2011
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	Comparison of time within therapeutic INR range with percentage INR within therapeutic range for assessing long-term anticoagulation control in children [reply to a rebuttal]	2011
Lilian Fairbairn Smith Dr Wei Cope Professor Farhad Kamali Dr Hilary Wynne	Effect of provision of the NHS NPSA oral anticoagulant therapy patient information pack upon patients' knowledge and anticoagulant control	2011
Dr Tina Biss Professor Ashley Adamson Emeritus Professor Chris Seal Professor Farhad Kamali	The potential impact of dietary vitamin K status on anticoagulation control in children receiving warfarin	2011
Dr Tina Biss Dr Peter Avery Professor Farhad Kamali	Warfarin treatment outcomes in children monitored at home with a point-of-care device	2011
Professor Ann Daly Professor Farhad Kamali	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives	2010
Professor Farhad Kamali Dr Hilary Wynne	Pharmacogenetics of warfarin	2010
Dr Peter Avery Professor Farhad Kamali	Proposal of a pharmacogenetic-based dosing algorithm for the induction of warfarin anticoagulation therapy in patients with thromboembolic disease	2010
Dr Montserrat Briz Del Blanco Dr Katherine Talks Dr John Hanley Dr Patrick Kesteven Professor Ann Daly et al.	Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study	2010
Professor Farhad Kamali	Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups	2010
Professor Farhad Kamali Professor Ann Daly	Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data	2009
Professor Farhad Kamali Professor Ann Daly	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study	2009
Professor Farhad Kamali Professor Ann Daly	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design	2009
Dr Katherine Talks Dr John Hanley Dr Patrick Kesteven Dr Peter Avery Professor Ann Daly et al.	Individualised oral vitamin K for reversal of warfarin excessive anticoagulation	2009
Professor Farhad Kamali	Novel oral anticoagulant and diet: the potential for interaction	2009
Professor Farhad Kamali Dr Hilary Wynne	Pharmacogenetics and anticoagulation therapy	2009
Professor Farhad Kamali Peter Wood Alan Ward	Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety	2009
Dr Ellen Hatch Dr Hilary Wynne Dr Peter Avery Professor Farhad Kamali	Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients	2008
Elizabeth Sconce Dr Hilary Wynne Professor Farhad Kamali	Factors Affecting Anticoagulation Response to Warfarin	2008
Professor Farhad Kamali	Individual Patient Meta-Analysis of Self-Monitoring of an Oral Anticoagulation Protocol	2008
Elizabeth Sconce Dr Peter Avery Dr Hilary Wynne Professor Farhad Kamali	Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: A pilot study	2008
Dr Ellen Hatch Elizabeth Sconce Dr Barry King Dr Hilary Wynne Professor Ann Daly et al.	Polymorphisms in genes associated with the vitamin K epoxide reductase complex do not affect warfarin dose requirement	2007
Elizabeth Sconce Dr Peter Avery Dr Hilary Wynne Professor Farhad Kamali	Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin	2007
Elizabeth Sconce Dr Hilary Wynne Professor Farhad Kamali	Vitamin K supplementation during oral anticoagulation: No real cause for concern [2]	2007
Dr Ellen Hatch Elizabeth Sconce Professor Ann Daly Professor Farhad Kamali	A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene	2006
Elizabeth Sconce Professor Ann Daly Dr Tayyaba Khan Dr Hilary Wynne Professor Farhad Kamali et al.	APOE genotype makes a small contribution to warfarin dose requirements	2006
Elizabeth Sconce Dr Tayyaba Khan Professor Ann Daly Dr Hilary Wynne Professor Farhad Kamali et al.	Apolipoprotein E polymorphisms do not make a clinically significant contribution to warfarin dose requirements	2006
Elizabeth Sconce Professor Farhad Kamali	Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: The need for a more tailored dosing regimen	2006
Dr Hilary Wynne Dr Tayyaba Khan Dr Peter Avery Peter Wood Professor Farhad Kamali et al.	Dietary related plasma vitamin C concentration has no effect on anticoagulation response to warfarin	2006
Professor Farhad Kamali	Genetic influences on the response to warfarin	2006
Elizabeth Sconce Dr Tayyaba Khan Professor Ann Daly Dr Hilary Wynne Professor Farhad Kamali et al.	Simvastatin results in a lower warfarin dose requirement due to a reduced clearance of warfarin	2006
Professor Farhad Kamali	The future prospects of pharmacogenetics in oral anticoagulation therapy	2006
Elizabeth Sconce Dr Tayyaba Khan Professor Ann Daly Dr Hilary Wynne Professor Farhad Kamali et al.	The impact of simvastatin on warfarin disposition and dose requirements	2006
Dr Barry King Dr Tayyaba Khan Professor Farhad Kamali Professor Ann Daly	[abstract] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism	2005
Chen Chen Professor Farhad Kamali	[abstract] Investigation of the effect of Chinese herbal medicines on the anticoagulation effect of warfarin using hepatic microsomes in vitro	2005
Elizabeth Sconce Dr Tayyaba Khan Dr Hilary Wynne Dr Patrick Kesteven Dr Peter Avery et al.	[abstract] Pfizer poster communication prize - The influence of patient age, CYP2C9 genotype and height on warfarin dose requirements	2005
Professor Farhad Kamali	A comparison of the antinociceptive and adverse effects of a mu-opioid receptor agonist with a delta-opioid receptor agonist	2005
Dr Tayyaba Khan Elizabeth Sconce Professor Farhad Kamali	Factors contributing to the stability of anticoagulation control and outcome of thromboembolic prophylaxis in the older population	2005
Elizabeth Sconce Dr Tayyaba Khan Dr Hilary Wynne Professor Farhad Kamali	Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation	2005
Elizabeth Sconce Dr Tayyaba Khan Dr Hilary Wynne Professor Farhad Kamali	Patients with unstable control have a poorer dietary intake of vitamin K compared with patients with stable control of anticoagulation	2005
Elizabeth Sconce Dr Tayyaba Khan Dr Hilary Wynne Dr Peter Avery Dr Barry King et al.	The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen	2005
Professor Farhad Kamali	V-10153 Vernalis	2005
Professor Farhad Kamali	V-10153 Vernalis. A New thrombolytic agent	2005
Professor Farhad Kamali Dr Tayyaba Khan Dr Barry King Dr Patrick Kesteven Peter Wood et al.	Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin	2004
Dr Tayyaba Khan Dr Hilary Wynne Dr Peter Avery Dr Patrick Kesteven Professor Farhad Kamali et al.	Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin	2004
Professor Farhad Kamali Dr Tayyaba Khan Dr Barry King Professor Ann Daly Dr Hilary Wynne et al.	The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements	2004
Dr Tayyaba Khan Professor Farhad Kamali Dr Patrick Kesteven Dr Peter Avery Dr Hilary Wynne et al.	The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation	2004
Dr Barry King Dr Tayyaba Khan Professor Farhad Kamali Professor Ann Daly	Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism	2004
Professor Farhad Kamali	[Book Review] Introduction to drug metabolism	2003
Dr Barry King Dr Tayyaba Khan Professor Farhad Kamali Professor Ann Daly	Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements	2003
Helen Hickmott Dr Hilary Wynne Professor Farhad Kamali	The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements	2003
Professor Farhad Kamali Dr Hilary Wynne	The effect of stability of oral anticoagulant therapy upon patient-perceived health status and quality of life [4]	2003
Dr Hilary Wynne Dr Patrick Kesteven Professor Farhad Kamali	The impact of stability of oral anticoagulant therapy upon patient perceived health status and quality of life	2003
Professor Farhad Kamali Professor Ann Daly Dr Hilary Wynne	Warfarin sensitivity: Be aware of genetic influence	2003
Professor Farhad Kamali	Stereoselectivity in thioridazine metabolism in vitro	2002
Professor Dorothy Newbury-Birch Dr Ray Lowry Professor Farhad Kamali	The changing pattern of drinking, illicit drug use, stress, anxiety and depression in dental students: a longitudinal study (authors reply)	2002
Professor Dorothy Newbury-Birch Dr Ray Lowry Professor Farhad Kamali	The changing patterns of drinking, illicit drug use, stress, anxiety and depression in dental students in a UK dental school: A longitudinal study	2002
Professor Farhad Kamali Dr Hilary Wynne	The impact of stability of oral anticoagulant therapy upon patient perceived health status and quality of life	2002
Professor Farhad Kamali	Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a Pk-PD modelling analysis.	2001
Professor Dorothy Newbury-Birch Dr David Walshaw Professor Farhad Kamali	Drink and drugs: From medical students to doctors	2001
Professor Dorothy Newbury-Birch Professor Farhad Kamali	Psychological stress, anxiety, depression, job satisfaction, and personality characteristics in preregistration house officers	2001
Professor Farhad Kamali Dr Hilary Wynne Dr Patrick Kesteven	Temporal variations in plasma vitamin K and lipid concentrations and clotting factor activity in humans	2001
Professor Farhad Kamali	Almotriptan Almirall Prodesfarma SA	2000
Professor Farhad Kamali Dr Tim Butler	The contribution of plasma (R)- and (S)-warfarin and vitamin K concentrations to intra-individual variability in anticoagulation	2000
Professor Farhad Kamali Dr Tim Butler Dr Hilary Wynne	The influence of (R)- and (S)-Warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation	2000
Professor Farhad Kamali	Alcohol and illicit drug use in medical students and junior doctors at Newcastle University: a longitudinal study	1999
Professor Farhad Kamali	Assessment of the relationship between analgesia and plasma concentrations of dihydrocodeine and dihydromorphine following dihydrocodeine administration	1999
Professor Farhad Kamali	BMS-181885-Bristol Myers Squibb	1999
Professor Farhad Kamali	Ditropan XL	1999
Professor Farhad Kamali	Ditropan-XL-Alza Corp	1999
Helen Hickmott Professor Farhad Kamali	Effect of racemic and (R)- and (S)-warfarin on carboxylase activity and the vitamin K cycle	1999
Professor Farhad Kamali	Job satisfaction and stress in pre-registration house officers in the north east of England	1999
Professor Farhad Kamali	KMD-3213-Kissei Pharmaceutical Co Ltd	1999
Professor Farhad Kamali Emeritus Professor Robin Seymour	Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth	1999
Professor Farhad Kamali	Rofecoxib- Merck & Co Inc	1999
Professor Farhad Kamali	Talsaclidine fumarate-Boehringer Ingelheim Corp	1999
Professor Farhad Kamali Dr David Ball Emeritus Professor Robin Seymour	The effect of multiple anticonvulsant therapy on the expression of phenytoin-induced gingival overgrowth	1999
Professor Farhad Kamali Russell Wallace Professor Alan Calvert	The safety of sumatriptan administration 2 h after subcutaneous injection of alniditan, a new anti-migraine drug, in healthy volunteers	1996